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Is there evidence for anticipation in autosomal-dominant polycystic
kidney disease? The heritability of autosomal-dominant polycystic kid-
ney disease (ADPKD) is marked by an apparent high mutation rate,
neonatal onset of disease in some patients and intrafamily variability.
These findings raise the possibility of genetic anticipation in ADPKD as
has been observed in fragile-X syndrome, myotonic dystrophy and
Huntington's disease. We reviewed 242 pedigrees obtained during our
prospective studies on the natural history of ADPKD. Anticipation was
defined as a 10 year earlier onset of ESRD in offspring as compared to
their affected parent or a child diagnosed in the first year of life. Due to
the slowly progressive nature of ADPKD, 148 pedigrees were uninfor-
mative. Anticipation of ESRD was found in 49% of informative families
in at least one parent-offspring pair, and when early onset children were
included, 53% of informative families had at least one parent-offspring
pair with anticipation. Moreover, the transmitting parent in the pairs
with anticipation was more often the mother than the father, similar to
myotonic dystrophy, where the most dramatic form of anticipation,
congenital disease, occurs almost exclusively with maternal transmis-
sion. These observations suggest that ADPKD may be another genetic
disorder characterized by heritable unstable DNA.
Until recent years genetic diseases were considered stable
disorders with constant phenotypes over many generations.
However, there were clinical examples which showed anticipa-
tion, that is, earlier onset and increased disease severity in
successive generations. Such phenotypic alterations had been
described in myotonic dystrophy [1, 2], Huntington's disease
[3, 4], spinocerebeilar ataxia type 1 [5], all autosomal dominant
diseases, and in fragile-X syndrome, an X-linked disease [6, 7].
In myotonic dystrophy the extreme of anticipation occurs with
a severe congenital form in some offspring of mothers with
classic adult onset disease [8]. In Huntington's disease, a subset
of patients with paternal disease transmission has an early age
of onset and severe disease [4]. Despite these clinical examples,
genetic anticipation was not embraced as a principle of inher-
itance because no molecular explanation existed. However,
recently a molecular basis for this phenomenon was found, first
in fragile-X syndrome [9—12], then in myotonic dystrophy
[13—17], and recently in Huntington's disease [18] and spino-
cerebellar ataxia type 1 [5]. In these disorders, progressive
amplification of DNA-triplet repeats within or adjacent to the
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disease gene occurs in successive generations, and this insta-
bility of DNA is associated with increasing disease severity [5,
9, 12, 18, 19]. Thus, it is now clear that genetic anticipation
secondary to heritable unstable DNA exists.
Autosomal-dominant polycystic kidney disease (ADPKD)
shares certain characteristics with myotonic dystrophy and
fragile-X syndrome, suggesting genetic anticipation may also
occur in ADPKD. ADPKD shows marked variability in disease
severity not only between but also within families [20]. As in
myotonic dystrophy, the most striking example of this pheno-
typic variability is the occurrence of ADPKD in utero or in the
neonatal period in some children whose parents have typical
adult onset disease [21]. Moreover, one third of ADPKD
patients have a negative family history [22—24] which could
reflect mild, clinically unsuspected disease in earlier genera-
tions. Because of these observations we hypothesized that
genetic anticipation occurs in ADPKD. Unlike diseases such as
myotonic dystrophy and Huntington's disease, age of onset is
difficult to define in ADPKD because it is often the age at
screening. Therefore, we used age at onset of ESRD as a
criterion for disease severity. However, ESRD is also influ-
enced by secondary disease processes such as hypertension and
infection [25—27]. Therefore, one woui .:'ect ESRD to occur
later in life in offspring than in their parents, particularly since
antihypertensive and anti-infectious medications became avail-
able in the early 1960's and would have been used to treat young
ADPKD adults born after 1930. Thus, if the offspring generation
reaches ESRD earlier in life than the parent generation in spite
of better treatment, this may represent more severe disease,
that is, anticipation.
Methods
Pedigrees of 242 ADPKD families were reviewed. Each
family had at least one member studied on the General Clinical
Research Center at the University of Colorado Health Sciences
Center or on the Pediatric Clinical Research Center at the
Children's Hospital between 1985 and 1993 as part of our
ongoing prospective study of ADPKD. Each patient visit in-
cluded a detailed history, physical exam, abdominal ultrasound,
and blood chemistry determinations including serum creatinine
concentration. Patients already in end-stage renal disease
(ESRD) were excluded from the study. Pedigrees were con-
structed with the information supplied by the patients. All
known affected family members were noted including known
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1. No one with ESRD and no known early affected
children
2. Second generation more than 10 years younger
than the first was at onset of ESRD:
3. First generation had died from causes other than
ESRD at an age less than 10 years older than
the second generation was at onset of ESRD:
4. Other causes for ESRD in addition to ADPKD
possible:
5. ESRD of the proband during follow-up but no
other family member known to be affected:
6. Insufficient information about the age at onset of
ESRD or uncertainty about the diagnosis of
ADPKD or cause of death in the parent
affected children. The ages of family members at death or at
onset of ESRD as well as the ages of affected family members
who did not have ESRD at the time of the proband's study visit
were noted. ESRD was defined as dialysis, transplantation or
death from uremia. We examined both families and individual
parent-offspring pairs for the occurrence of anticipation. Antic-
ipation in a family was defined by one of two criteria. Any
family with an affected parent and a child diagnosed with
polycystic kidney disease in utero or in the first year of life was
considered to manifest anticipation. Except for one of these
families both the affected child and parent have been seen and
examined by us. In addition, a 10 year earlier onset of ESRD in
the offspring of any parent-offspring ADPKD pair in a family
was considered evidence for anticipation in that family. The
parent need not have reached ESRD for a parent-offspring pair
to meet this criterion. For example, an ADPKD patient who
entered ESRD at age 40 whose affected parent was still alive
without ESRD at age 64 would meet the criterion. Since ESRD
occurs in only about 50% of affected patients by age sixty [25,
281 and many patients with ADPKD do not reach ESRD during
their lifetime, not all families were informative in regard to this
criterion of anticipation. We also analyzed every parent-off-
spring pair of the 86 informative families. Because effective
medications for hypertension and infection became generally
available in the early 1960's, we noted whether one or both of
parent-offspring pairs were born before 1930 and therefore were
not likely to have received the benefits of these treatments.
Results
Two hundred and forty-two pedigrees were reviewed (Fig. 1).
In 148 families there were insufficient data to decide whether
they showed anticipation in any parent-offspring pair. In almost
all of these families insufficient data was due to the slowly
progressive nature of the disease (Table 1). In nine families only
the study proband who developed ESRD was known to have
ADPKD. In four of these nine families the parents had not
undergone any imaging study; in five families both parents had
been examined with ultrasound at ages 57 to 82 years and were
negative, whereas their children developed ESRD at ages 34 to
46 years. These families could represent either new mutations
or anticipation with one of the parents carrying a premutation
(as has been shown in fragile-X syndrome), but they were not
considered to demonstrate anticipation in this study. In only
two families it was not possible to classify the family because of
D: 53 1990
2 M: 59 ?
D: 45 ?
3 M: 51 1975
D: 33 19854 M: 67 1985
D: 47 19885 M: — — no ESRD age 44 (1993);
ADPKD dx age 33 by
US; IVP neg. age 24
D: 16 1989 RR ADPKD dx at birth6 M: — — D no ESRD age 60 (1977);
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emboli; ADPKD dx
on autopsy
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D: 41 19899 M: 54 1948
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13 M: —
D: 3 1981
14 M: 51 1949
D: 39 1971
15 M: 72 1971
D: 51 1987
16 M: — —
Table 1. Families with insufficient information
86 families
43 families
Table 2. Families with a parent-child pair showing anticipation of
ESRD
Age at Year Age
ESRD of No ESRD difference
Family year ESRD RR/D age/year years
A: Transmissions from mother to daughter (N = 17)
5 families 1 M: — — — Scr 1.5 mg/dl age 77(1989); ADPKD dx
age 61 by IVP3 families
9 families
2 families
RR
DU
RR
RR
RR
RR
RR
>24
14
18
20
>28
>13
24
12
10
30
30
22
16
>17
12
21
RR
RR
RR
RR
RR
DU
DU
RR
RR
D
RR
RR
RR
RR
RR
DU
RR
DU
RR
D
1982
1987
1989
1992
died 1981 of heart and
kidney failure;
ADPKD dx during
surgery (1975)
Scr 1.0 mg/dl age 20
(1981); ADPKD dx
age 3 yr by IVP
ADPKD dx age 7
months
Scr 3.7 mg/dl age 66(1972) at death; died
of congestive heart
failure
D: 54 1985 RR >12
lack of information on the age at onset of ESRD, or because the
diagnosis or the cause of death of the parent were unknown.
There were 86 families in whom information was sufficient to
diagnose or exclude anticipation of ESRD in any parent-
offspring pair. Forty-four families (51%) did not show anticipa-
tion, 42 (49%) did (Table 2); there were six families with two
parent-offspring pairs with ESRD anticipation, and two families
with 3 pairs. In one family (family 26 of Table 2) all three
children of the affected mother showed anticipation of ESRD,
with differences of 26, 20 and 10 years. The mean age difference
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B: Transmissions from mother to son (N = 17)
17 M: 42 1954 DU
5: 32 1967 DU
14b M: 51 1949 DU
5: 33 1962 DU6C M: — — D no ESRD age 60 (1977);
died of pulmonary
emboli; ADPKD dx
on autopsy
1984 RR
— D no ESRD age 64 (1974);
died of a cerebral
hemorrhage; ADPKD
by pedigree data(father, sister and son
affected)
1989 RR
— D no ESRD age 42 (1968);
died of a ruptured
aneurysm; ADPKD
dx on autopsy
1977 RR
1976 RR
1974 RR
— D no ESRD age 70 (1980);
died of colon cancer;
ADPKD dx on
surgery age 29
1990 RR
1970 DU
1990 RR
— — no ESRD age 38 (1992);
ADPKD dx age 33 by
CT-scan
1988 RR ADPKD dx at birth
1966 RR
1981 RR
1969 RR
1982 RR
1969 RR
1974 RR
1963 DU
1977 RR
1964 DU
1969 RR
1976 RR
1970 RR
1988 RR
1993 RR
Age at Year Age
ESRD of No ESRD difference
Family year ESRD RE/D age/year years
C: Transmissions from father to son (N = 12)
28 F: — — D no ESRD age 71(1992);
ADPKD dx age 49;
died of pulmonary
emboli
D: Transmissions from father to daughter (N = 6)
38 F: 64 1950 DU
D: 48 1976 RR
39 F: 57 1971 DU
D: 44 1990 RR
40 F: 53 1969 DU
D: 39 1980 RR
41 F: — — — S1.9mg/dlage53
(1992); ADPKD dx
age 50 by US, no
D: 29 1991 RR
42 F: 79 1987 RR
D: 45 1988 RR 34
10' F: 48 1961 DU
D: 34 1985 RR 14
a Dl and D2 are sistersb Thismother also had a daughter with anticipation of ESRD listed as
family 14 in Table 2a
14 C Thismother also had a daughter with anticipation of ESRD listed as
family 6 in Table 2a
These 2 mothers were aunt and niece
C Ml and M2 are sisters
51, 52 and 53 are brothers. In this family all affected children
showed major anticipation.gThis family had two other parent-offspring pairs with anticipation
listed as family 10 in Table 2a and 2d.h This family had another parent-offspring pair with anticipation
listed as family 27 in Table 2b.
This family had two other parent-offspring pairs with anticipation
listed as family 10 in Table 2a and 2c.
Abbreviations are: M, mother; D, daughter; F, father; 5, son; dx,
diagnosed; RR, renal replacement therapy; D, death; DU, death from
uremia; CT, computed tomography; 5cr. serum creatinine; IVP, intra-
venous pyelogram; US, ultrasound; neg., negative.
diagnosed with enlarged kidneys at birth, and at age three
months she had severe hypertension. The maternal grandfather
had ADPKD proven on autopsy, but the child's mother was
Table 2. Continued
Age at Year Age
ESRD of No ESRD difference
Family year ESRD RRID age/year years
Table 2. Continued
10
18
5:
29 F:
5:
30 F:
>12 5:
31 F:
5:
32 F:
5:
33 F:
5:
>10 34 F:
5:l0 F:
5:
27" F:
>17 5:
35 F:
21 S:
36 F:
5:
37 F:
5:
35 1981 RR
54 1967 DU
33 1984 RR
64 ? DU
48 1970 RR
69 1987 RR
37 1987 RR
54 ? DU
42 1988 RR
64 1967 DU
42 1966 DU
59 1956 DU
44 1972 RR
48 1961 DU
31 1976 RR
62 ? DU
49 1973 RR
47 1964 DU
37 1979 RR
54 1977 RR
44 1992 RR
49 1958 DU
35 1980 RR
5: 48
18 M: —
5: 54
19 M:" —
5: 25
M:" 54
5: 3320 M: —
5: 57
21 M: 60
5: 49
22 M: —
5: 4
23 M:e 46
SI; 33
M2:t 51
52: 4024 M: 52
5: 39
25 M: 52
5: 39
26 M: 60
SI:1 34
S2: 50
S3:r 40
27 M: 58
5: 44
>36
21
16
32
12
22
15
17
13
10
10
14
16
13
14
>24
>13
11
>34
13
11
13
13
26
10
20
symptoms
at onset of ESRD between parents and offspring of all antici-
pation pairs was 18 years. In those 11 parents who did not have
ESRD, the age at last evaluation or death was taken for the
calculation of the age difference, therefore the real age differ-
ence is greater. There were 16 pairs with an age difference of
more than 20 years and six with a difference of 30 years or
more.
There were 14 families with 18 early onset children. All were
born to mothers with adult onset disease and normal renal
function. Eight families with 11 early onset children have been
described by us previously [211. Here we include another six
families. In one family a child was diagnosed in utero and was
seen once again at six months of age. Another child was
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242 families
negative for ADPKD on intravenous pyelography at age 24
years. The earlier findings of this family have been published
elsewhere [29]. Subsequently we studied other family members.
The child was in ESRD at age 16 years, and her mother was
found to have renal cysts on ultrasound at age 33 years; now she
is 44 years old with adequate renal function. Four families had
a child diagnosed at birth (2 children) or in utero (2 children)
elsewhere. Three of these children were referred to us at the
ages of nine months, 2.5, and 10 years; the latter two children
were hypertensive, and the 2.5-year-old had required antihy-
pertensive medications since age six months.
Of the 11 early onset children reported previously two had
ESRD at age 3.5 and 4 years [21] and therefore showed
anticipation of ESRD, as did the 16-year-old girl described
above. In addition, three families with six early onset children
showed anticipation of ESRD in another parent-offspring pair.
Therefore, six families with early onset children are listed in
Table 2 among the 42 families showing anticipation of ESRD,
but there are eight additional families with one or more early
onset children but without ESRD in that family (Fig. 1). Thus,
overall, 50 of 94 families (53%) met one or both of the criteria
for phenotypic anticipation of ADPKD.
Four representative pedigrees with evidence for anticipation
are shown in Figure 2 A—D. In family A all affected persons
(11-1, 111-i, IV-l) were studied by us. The first generation (I) did
not have any history of renal disease or hypertension with the
mother (I-i) dying at age 84 of an abdominal cancer and the
father (1-2) at age 70 of a bleeding gastrointestinal ulcer. The
affected woman of the second generation (11-1) was diagnosed
with ADPKD four years after the diagnosis was made in her
daughter (111-1). At her (11-1) study visit in 1989 at age 77 years
she had bilaterally enlarged kidneys with multiple cysts and
mild hypertension, but a serum creatinine concentration of 1.5
mg/dl. Her daughter (111-1) had renal failure with a serum
creatinine concentration of 5.6 mgldl in 1989 and began hemo-
dialysis one year later at an age of 53 years. Her offspring (IV- 1)
is still too young to compare her disease course with that of her
mother, but at age 20 years she has 6 to 15 cysts bilaterally with
normal renal function.
In family B two generations are affected. The first generation
(I) died without a history of renal disease. In the next generation
(II) two sisters have ADPKD, one without ESRD at age 63
Fig. 1. Two hundred and forty-two pedigrees
were available for analysis. A total of 148
were uninformative (Table 1); 86 families were
informative with 42 showing anticipation of
ESRD; 8 additional families had early onset
children. Therefore 53% of 94 informative
families showed phenotypic anticipation of
ADPKD.
(11-4) and the other with renal replacement therapy at age 66
years (11-2). There are three affected children of patient 11-2.
Two daughters (111-1 and 111-2) were in ESRD at ages 44 and 50
years, 22 and 16 years earlier than their mother. The son (111-3)
has adequate renal function, but he is still more than 10 years
younger than his mother was at onset of ESRD.
In family C the affected parent in the first generation (1-2) died
from uremia at age 59 years. The course of her four affected
children was very different: The first son (11-1) died at age 71
without ESRD; the second son (11-3) began dialysis at age 57
years; the two other affected children (IT-S and 11-6) are not in
ESRD at ages 60 and 52 years. The children of 11-1 again have
very different courses. One son (111-1) was in ESRD at age 35
years, the other son (111-3) has only slightly impaired renal
function at age 41 years. The children of 11-3 are more than 10
years younger than their parent was at onset of ESRD, there-
fore their disease course cannot yet be compared to that of their
father. But 111-6 has a child who was diagnosed in utero with
bilaterally enlarged and hyperechoic kidneys (IV-3). A fol-
low-up ultrasound study at six weeks of age showed bilateral
renal cysts, and at age seven years she is hypertensive, with her
renal ultrasound showing an enlarged right kidney with six cysts
and a normally-sized left kidney with four cysts. Therefore,
apparent anticipation occurred twice in this family, in the
parent-child pair 11-1 to III-! with earlier onset of ESRD and in
the pair 111-5 to IV-3 with an early onset child.
In family D the great-grandparent (I-i) died of ESRD at age
64. One of his children began dialysis at age 48 (11-1) and the
other at age 57 (11-3). Patient II-! has two affected daughters:
One (111-5) has normal renal function at age 39 but she has two
children diagnosed with ADPKD in utero (TV-S and IV-8), one
of whom was therapeutically aborted because of large hyper-
echoic kidneys and severe oligohydramnios (IV-8). The other
child (IV-5) had medically treated hypertension since age two
years, and at age 12 she has bilaterally enlarged kidneys with
more than 15 cysts, greatly reduced urinary concentrating
ability but normal creatinine clearance.
In order to determine the actual frequency of anticipation and
whether there was any consistency in the pattern of anticipation
in these families, we examined every parent-offspring pair of
the 86 informative families (Table 3). There were 359 parent-
offspring pairs with at least one member who had reached
148 Insufficient data
for ESRD
(see Table 1)
V
8 Families with
early onset children
but no ESRD
42 Families with/ anticipation of ESRD
(49% of 86 families)
50 Families with
clinical anticipation
(53% of 94 families)
86 Sufficient data
for ESRD/j
44 Families
without anticipation
of ESRD
(51% of 86 families,
47% of 94 families)
Fick et a!: Anticipation in ADPKD 1157
ESRD. One hundred and thirty-eight parent-offspring pairs
(38%) were uninformative because the second generation was
still more than 10 years younger than the first was at onset of
ESRD (N = 93), or because the first generation died at an age
less than 10 years older than the second was at onset of ESRD
(N = 1), or because the exact age at onset of ESRD or the cause
of death was unknown (N = 44); these missing data were
noticed mainly in the parent and grandparent generations or for
more distant relatives.
Of the 221 informative parent-offspring pairs, 52 (24%)
showed anticipation of ESRD (Table 3). In 33 pairs (15%) the
1Ø2
ESAD age 59
5j 61
No ESRD ESRD Age 57 I No ESAD No ESRD
Age7l Age6O Age5212fl I 5 6 8j
ESRD
Age3 Sct5rng/d,17rng/dl
Sc,0.9 g/ NOESRD
Sc 0.7 mg/dI S, 1.0 mg/dl ADPKD diagnosed
Agel3 Agel6 inutero
1n
S5, 2.7 mgldl
Age44
1 2 3
Sc, 0.9 mg/dl
Age 20
offspring had ESRD two to nine years earlier than the parent.
Because they had ESRD earlier than their parent in spite of
availability of better treatment modalities for hypertension and
infection, they also might be considered to show anticipation.
Thirteen offspring (6%) entered ESRD at the same age (± 1
year) as their parent. Sixty offspring (27%) had no ESRD at the
time of last evaluation but were still up to 10 years younger than
their parent was at onset of ESRD. Twenty-one offspring (10%)
entered ESRD two to nine years later than their parent, and 25
offspring (11%) had not yet reached ESRD at an age one to nine
years older than their parent was at onset of ESRD. In only 17
parent-offspring pairs (8%) did the offspring do better than the
parent by a difference of 10 or more years, having ESRD 10 or
more years later than the parent (N = 8) or not being in ESRD
at an age 10 or more years older than the parent (N = 9).
Because in our study of early onset children the affected
parent was the mother in all 18 parent-child pairs, we assessed
if there was an effect of gender among parent-offspring pairs
with earlier onset of ESRD as well. Of the 52 parent-offspring
pairs with ESRD anticipation the affected parent was the
mother in 34 pairs (65%) and the father in 18 pairs, thus
demonstrating a predominance of anticipation with maternal
gene transmission. Overall, the transmitting parent was the
mother in 64% of 85 parent-offspring pairs where the offspring
did worse than the parent, whereas the transmitting parent was
Died age 84
A
II
ESRO Age
Sr 0.8 mgldl
Age 20
B
ESRD!
D
2 3
ESRDIJEII
ESAD Age 57
lv
III
ESRD ESRD No ESRD
Age 50 Age 44 Age 48
Fig. 2. Pedigrees of four families showing anticipation of ESRD.
Families C and D have one or more children with a diagnosis of
ADPKD in utero in addition to anticipation of ESRD. For clarity some
of the unaffected siblings in the four families have not been depicted.
Symbols are: (U) male, affected; (0) female, unaffected; () deceased;
() fetus; (C) suspicious for ADPKD, Abbreviations are: Sr, serum
creatinine concentration; ESRD, end-stage renal disease; WKS, weeks;
DX, diagnosed; SAB, spontaneous abortion.
t 5 6
Sc 1.2 mg/dl
Age 39
4a5.6o7
ADPXD SAB 1 Cyst
DX 19 wkS Age 10
36 wks
gestation
Fig. 2. Continued
8
Male SAB
ADPKD 12 wkS
Dx
24 wks
gestation
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Table 3. Analysis of 359 parent-offspring pairs with at least one
member with ESRD from the 86 informative families (138
uninformative pairs (38%) (see text); 221 informative pairs]
No. of parent-
offspring pairs
Parent, offspring
born before l930
Y,Y Y,N N,N
1. Anticipation of ESRD: 52 (24%) 8 39 5
(second generation had
ESRD 10 or more years
earlier than the first)
2. Offspring doing worse than 33 (15%) 14 18 1
parent: (second
generation had ESRD 2
to 9 years earlier than
the first)
3. Offspring had same course 13 (6%) 3 9 I
as parent: (second
generation had ESRD at
the same age as the first,
1 year)
4. Indeterminate: (second 60 (27%) 1 53 6
generation has no ESRD
but is still 0 to 10 years
younger than the first)
5. Offspring doing better than 46 (21%) 23 23 0
parent:
a. (second generation had 21
ESRD 2 to 9 years later
than the first)
b. (second generation has 25
no ESRD and is 1 to 9
years older than the first
at onset of ESRD)
6. Offspring doing better than 17 (8%) 14 3 0
parent by more than 10
years:
a. (second generation had 8
ESRD 10 or more years
later than the first)
b. (second generation has 9
no ESRD and is 10 or
more years older than
the first was at onset of
ESRD)
a y,y indicates both parent and offspring born before 1930; Y,N
indicates parent born before 1930, offspring after 1930; N,N indicates
both parent and offspring born after 1930.
the mother in only 43% of the 63 parent-offspring pairs where
the offspring did better (P < 0.05).
Discussion
This study has demonstrated that in 53% of informative
families and 24% of informative parent-offspring pairs the
clinical presentation of ADPKD is suggestive of genetic antic-
ipation. Anticipation in ADPKD was first suggested by Cairns
in 1925 who observed an earlier age at first symptoms or death
in the younger generation of seven families [30]. Later, Werner
reported that in 12 of 14 ADPKD families, several members of
the second generation died at a significantly younger age than
the first [31]. The age difference at death was more than 10 years
in eight families (mean 19 years for 12 two-generation pairs).
Dalgaard also observed an earlier age at onset of symptoms or
death in the younger generation of 12 families, but he could not
document statistical significance for this and dismissed antici-
pation [22]. The rejection of the concept of anticipation in
ADPKD resulted from lack of large populations available for
study, lack of a specific endpoint such as ESRD, and lack of a
plausible genetic mechanism. In fact, since the mid-forties
examples of anticipation were dismissed by geneticists as
reflecting ascertainment bias [1].
In 1989 a study of 14 myotonic dystrophy families showed
that the age at onset of symptoms was at least one decade
earlier in 60 out of 61 parent-child pairs, and that an earlier age
of onset was associated with more severe disease [2]. Similar
increases in disease severity in successive generations were
observed in fragile-X syndrome [6, 7] and in a subset of patients
with Huntington's disease with paternal gene transmission [3,
4].
Heritable unstable DNA was first documented in fragile-X
syndrome as the molecular mechanism underlying anticipation.
Progressive amplification of a CCG triplet repeat within the
FMR-l gene occurs when the gene is transmitted by mothers
[9—12]. This is associated with an increase in disease severity in
sons of carrier women as opposed to the fathers of these women
who were phenotypically-normal transmitting males. Similarly,
the numbers of CTG triplet repeats at the 3' end of the myotonin
protein kinase gene, which is responsible for tnyotonic dystro-
phy, can increase markedly in successive generations, and this
correlates with disease severity [13—15, 17, 19]. Most recently,
the genes for Huntington's disease [18] and spinocerebellar
ataxia type 1 [5] were identified. They also contain unstable
triplet repeats, (CAG), and the largest expansions were found
in juvenile onset cases [5, 18].
We have recently reported on 11 children from eight ADPKD
families who were diagnosed in utero or in their first year of life
[211. They had marked structural and functional disease pro-
gression in early childhood (mean age 6.8 years), with two
children reaching ESRD at ages 3.5 and 4 years. In contrast, all
their affected parents had normal renal function in adulthood
[21]. Moreover, a review of the literature reveals 68 children
with a diagnosis of ADPKD in utero or in the first year of life
[21]. Most of those children were severely affected with greatly
enlarged kidneys at birth or on prenatal ultrasound, and on
follow-up 34 had died within the first year of life. In contrast,
60% of their affected parents did not even know of their own
disease until the birth of an affected child. Therefore, these
early diagnosed children do not simply represent more intensive
prenatal screening. Moreover, we have screened 23 at-risk
fetuses and the only fetuses with ADPKD diagnosed in utero
(N = 2) were those with another early onset sibling. This and
their more severe course argue against their diagnosis resulting
only from more intensive screening. The early onset ADPKD
children are similar to the children with congenital myotonic
dystrophy whose mothers have the more common "adult" type
of myotonic dystrophy [8]. Another similarity between ADPKD
in our study and myotonic dystrophy is the striking predomi-
nance of mothers who transmitted the congenital form of the
disease [8, 21].
Investigators have speculated about the mechanism for early
and severe ADPKD manifestation [32]. A double dose of a
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dominant gene, or chance inheritance of both the ADPKD and
autosomal-recessive polycystic kidney disease gene, or the
influence of "modifying alleles" have been suggested [33—35].
Since there are no reported examples of early onset children
with both parents being affected, and since early onset children
have been observed in a family with two different fathers [351
and in cousins and uncles [32, 36], neither a double dose of the
ADPKD gene nor other genetic factors transmitted by the
unaffected parent seem to account for early disease manifesta-
tion. An effect of changes in the gene itself as occurs with
heritable unstable DNA seems to be the best explanation.
Given these observations in early onset children it seemed
important to examine whether anticipation could be demon-
strated more broadly. A prospective longitudinal study to
investigate this is virtually impossible since ADPKD develops
over decades and at least two generations have to be studied.
Therefore, we reviewed the pedigrees collected during our
prospective studies. Since we excluded persons with ESRD
from our study, a bias towards more severe disease in our index
patients is unlikely. As the criterion for anticipation we chose a
10 year or greater difference in the age at onset of ESRD. This
is much more precise than age at onset of symptoms which was
used in myotonic dystrophy [21 and Huntington's disease [3, 4].
Also, age at diagnosis is imprecise in ADPKD since it is often
the age of screening.
Our criterion is not only precise but also conservative. Since
ESRD is also influenced by secondary processes such as
hypertension and infection, the recent increased awareness of
the disease and improved treatment modalities for hypertension
and infections should lead to a substantial delay of ESRD in the
younger generations. Therefore, it is not unexpected that we
found this in 63 of 221 informative parent-offspring pairs (29%).
Of these, 26 parents were born before 1930 whereas their
children were born after 1930 and therefore were likely to have
received antihypertensive medication at an age early enough to
influence progression of renal disease. However, 52 parent-
offspring pairs (24%) showed major anticipation of ESRD of
10 years, and in addition, 33 pairs (15%) showed an earlier
onset of ESRD of two to nine years in the second generation. In
63 of the 85 pairs with earlier onset of ESRD in the second
generation, the younger generation was born after 1930, and
therefore antihypertensive treatment was available for them at
an early age in contrast to their parents. This substantial
decrease in the age at ESRD in the offspring as compared to the
parent, with a difference up to more than 30 years, is unex-
pected and suggests a different genetic process in the offspring
than the parent. One possible explanation is heritable unstable
DNA.
Another possible explanation might be the interaction of the
ADPKD gene with other modifying genes, for instance with
genes such as renin or angiotensinogen. This hypothesis has not
yet been tested.
The fact that we observed apparent anticipation only in some
members of a family is consistent with the hypothesis of
underlying unstable DNA. Different copy numbers and pheno-
types have been shown in sibships with fragile-X syndrome [9,
37], myotonic dystrophy [15, 38], and Huntington's disease
[18]. Thus, expansion of the triplet repeat does not occur in
every meiosis, resulting in different disease severity within a
family.
Moreover, recently several myotonic dystrophy families
have been reported where an expanded allele decreased in size
to lower or even normal copy numbers during transmission
from an affected father to his children [39—41]; all these off-
spring are asymptomatic. This reverse mutation offers an ex-
planation for incomplete penetrance in myotonic dystrophy [39]
and possibly in ADPKD.
Anticipation in ADPKD does not occur as consistently as in
myotonic dystrophy. Likewise, in all three neurological dis-
eases with underlying unstable CAG repeats clinical anticipa-
tion is not the rule. In Huntington's disease, only 6% of affected
fathers have offspring with significant anticipation [3]. In spi-
nocerebellar ataxia type 1 there is a subset of patients with
juvenile onset and more rapid disease progression who have the
greatest triplet repeat numbers [5]. X-linked spinal and bulbar
muscular atrophy has an amplified CAG repeat in the androgen
receptor gene with a tendency to increasing triplet repeat
numbers in successive generations [42] and correlation between
repeat length and clinical severity [43]. The range of expansion
in these three neurological diseases is much smaller than in
fragile-X syndrome and myotonic dystrophy, and both in-
creases and decreases in length are observed.
Heritable unstable DNA would also explain family clustering
of early onset children [8, 21]. Once a critical copy number
occurs in the parent, there is a propensity for further amplifi-
cation of the gene [12, 44]. Thus, with this critical copy number
each meiosis is more likely to result in even larger copy
numbers, producing family clustering of severely affected chil-
dren. This has been demonstrated for myotonic dystrophy;
mothers of children with congenital disease had much longer
repeats than mothers of children with noncongenital disease
[45].
Another important feature of diseases caused by unstable
DNA is an apparent high mutation rate reflecting change from
premutation copy numbers in the parent to full mutation copy
numbers in offspring. From linkage studies there is evidence
that myotonic dystrophy may have been caused by a single
ancestral mutation [14, 46] which was passed on through many
generations without producing symptoms until it reached a
critical length associated with clinical symptoms [1, 45]. Phe-
notypically these persons seem to be new mutations, although
their parents already carry the premutation. This change from
premutation to full mutation has been proven in fragile-X
syndrome. Clinically, the spontaneous mutation rate seemed to
be high, but when parents and grandparents of patients with
seemingly new mutations were studied by DNA analysis, not a
single new mutation was found [12, 47, 48].
ADPKD also has a seemingly high spontaneous mutation
rate. Dalgaard found that 80 of 242 cases were isolated or
sporadic [22]. He concluded that these patients either repre-
sented new mutations or had parents with mild disease which
could not be diagnosed clinically. In this regard it is interesting
that even in recent years about half of ADPKD cases are
diagnosed only at autopsy [23]. In our study, 24% of the
patients have no family history of ADPKD. Moreover, of the 11
affected parents in our study who were not in ESRD but whose
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offspring were on renal replacement therapy, seven were diag-
nosed only after the diagnosis had been made in their offspring;
in two of them previously unsuspected ADPKD was found on
autopsy. Without careful studies the disease in the parents
would have been missed and their children considered new
mutations. Even those parents who do not show renal cysts on
ultrasound could carry a premutation as has been shown in
fragile-X syndrome and myotonic dystrophy [19, 47]. At this
point we cannot assess this latter possibility in ADPKD.
Recent findings of linkage disequilibrium between a closely
linked marker, D16S94, and the ADPKD1 locus on chromo-
some 16 also support a low spontaneous mutation rate [49].
With a high mutation rate one would expect every new mutation
to occur on a different chromosomal background, and therefore
linkage disequilibrium would not occur. Linkage disequilibrium
is an important characteristic of the other diseases with unsta-
ble DNA repeats [46, 50—53].
Unlike fragile-X syndrome and myotonic dystrophy, which
seem to be due to a single site of gene mutation [44], ADPKD is
caused by at least two different gene mutations [54, 55].
However, the ADPKD1 gene located on chromosome 16 ac-
counts for about 90% of cases [56]. One of our families known
to be of the non-ADPKD1 genotype was not included in this
analysis. The few persons in this family who entered ESRD
were usually in their sixties or seventies, so that the offspring-
generation is still too young to compare their disease course to
that of their parents. However, there are no early onset children
in this family, and we did not observe anticipation of ESRD.
Underlying heritable unstable DNA could also provide an
explanation for the variability of extrarenal manifestations in
ADPKD [57]. An intriguing aspect of heritable unstable DNA is
its somatic instability with high copy numbers [9, 12, 14, 151
such that different tissues and even different cells in a single
tissue do not contain exactly the same genes [44]. Such tissue
presence of DNA repeats.
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